Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06128629 · ClinicalTrials.gov registry record · Phase 3
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
A Phase 3 study of Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, sponsored by Intellia Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
- 20
- Study locations
NCT06128629: Active Phase 3 study of Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, sponsored by Intellia Therapeutics.
NCT06128629 is a Phase 3 study of Transthyretin Amyloidosis (ATTR) With Cardiomyopathy that is active but no longer recruiting, run by Intellia Therapeutics. The registered enrollment target is 1,200 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06128629, a Phase 3 study of Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, is active but no longer recruiting, sponsored by Intellia Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL NTLA-2001
Study Locations (20)
California
- Cedars-Sinai Medical Center - Los Angeles
- Western Greater Los Angeles VA Medical Center - Los Angeles
- Stanford University - Palo Alto
- University of California, San Diego (UCSD) - Medical Center - San Diego
Florida
- Mayo Clinic - Jacksonville - Jacksonville
- Cleveland Clinic of Florida - Weston
Massachusetts
- Brigham and Women's Hospital - Boston
- Boston University School of Medicine - Boston
Arizona
- University of Arizona - Tucson
Colorado
- University of Colorado Denver - Denver
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- MedStar Washington Hospital Center - MedStar Heart and Vascular Institute - Washington D.C.
Georgia
- Emory University School of Medicine - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2023-12-13 |
| Est. Completion | 2028-04 |
| Phase | Phase 3 |
What the registry record for NCT06128629 still lists
NCT06128629 is an interventional study that assigns participants to a tested intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% higher).
The record links to 1 condition, with Transthyretin Amyloidosis (ATTR) With Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06128629 names 20 study sites across 15 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06128629 about?
NCT06128629 is a clinical study titled "MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)". To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
What is the current status of trial NCT06128629?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2023-12-13. Estimated completion is 2028-04.
What conditions does trial NCT06128629 study?
This clinical trial studies the following conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy.
What interventions are being tested in trial NCT06128629?
The interventions under investigation include: Placebo (DRUG), NTLA-2001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06128629?
This trial is sponsored by Intellia Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06128629 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06128629's enrollment target sits among peer trials
1,200 220th of 2000 higher than 1,774 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
ACTIVE NOT RECRUITING · Phase 3
-
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI